跳到正文
BioPharm International·· 12 天前AI 评分50

问答解读注射用生物制品无菌保证与 EU GMP Annex 1、FDA 无菌工艺要求

FAQ: Sterility Assurance for Injectable Biologics

AI 导读

该问答梳理注射用生物制品无法终端灭菌时的无菌保证依据,涵盖无菌工艺、污染控制与验证。文章援引 EU GMP Annex 1 指出终产品在可行时应尽可能终端灭菌,并援引 FDA 无菌工艺指南建议仅在终端灭菌不可行时采用无菌工艺。对热或辐射敏感的生物制品需将产品、容器与密封件分别灭菌后在受控环境中组合,无菌保证取决于设施设计、工艺控制与人员操作。

正文 · 原文

News|Events|November 10, 2026

This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.

European Union good manufacturing practice (GMP) Annex 1 states that finished products should be terminally sterilized where possible, because a validated terminal step provides greater sterility assurance than sterile filtration or aseptic processing.1 FDA's aseptic processing guidance is similarly direct, recommending that sterile drugs should be made by aseptic processing only when terminal sterilization is not feasible.2 For many biologics this step is not feasible because heat or radiation can damage the molecule. The product, container, and closure are sterilized separately and combined in a tightly controlled environment, so sterility assurance depends on facility design, process controls, and operator behavior.2 US sterile manufacturing also falls under broader current GMP (cGMP) requirements, which was outlined earlier by Regulatory Compliance Associates’s Susan J. Schniepp in an overview of cGMPs for sterile manufacturing.3

Related to this article

Sad blue-grey eyes of elderly woman looking to the side, extreme close-up shot | Image credit: © pressmaster - © pressmaster - stock.adobe.com

November 5th, 2026

VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.

Read more

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

November 3rd, 2026

Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.

Read more

Cancer cells forming a solid tumor mass, with detailed cell structure and environment | Image credit: © Ummeya - © Ummeya - stock.adobe.com

November 2nd, 2026

CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.

Read more

Elderly man suffering from psoriasis on hands | Image credit: © and.one - © and.one - stock.adobe.com

November 9th, 2026

Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.

Read more

Doctor holding a digital tablet with x-ray of the 3D head of the patient with pain on the neck. Migraine headache concept | Image credit: © steph photographies - © steph photographies - stock.adobe.com

November 6th, 2026

Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.

Read more

3D rendered medical illustration of male anatomy showing the liver. | Image Credit: © Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com

November 5th, 2026

Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.

Read more

Q&A: What AI Reveals That Scientists Could Not See Before

November 4th, 2026

Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.

Read more

Hand inserts a molecule into DNA. | Image credit: © natali_mis - © natali_mis - stock.adobe.com

November 4th, 2026

Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.

Read more

来源:BioPharm International · biopharminternational.com